<SEC-DOCUMENT>0001683168-17-001637.txt : 20170621
<SEC-HEADER>0001683168-17-001637.hdr.sgml : 20170621
<ACCEPTANCE-DATETIME>20170621082214
ACCESSION NUMBER:		0001683168-17-001637
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170601
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170621
DATE AS OF CHANGE:		20170621

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SIMULATIONS PLUS INC
		CENTRAL INDEX KEY:			0001023459
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN [7373]
		IRS NUMBER:				954595609
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32046
		FILM NUMBER:		17922051

	BUSINESS ADDRESS:	
		STREET 1:		42505 10TH STREET WEST
		CITY:			LANCASTER
		STATE:			CA
		ZIP:			93534-7059
		BUSINESS PHONE:		661-723-7723

	MAIL ADDRESS:	
		STREET 1:		42505 10TH STREET WEST
		CITY:			LANCASTER
		STATE:			CA
		ZIP:			93534-7059
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>simulations_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 12pt">UNITED STATES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>The Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report (Date of earliest event reported)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 3.75in; text-align: center; text-indent: -3.75in">June 1,
2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Simulations Plus, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its
charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>California</U></B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>001-32046</U></B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>95-4595609</U></B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction <BR>
of incorporation)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Commission<BR>
File Number)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer</FONT><BR>
<FONT STYLE="font-size: 10pt">Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>42505 10th Street West, Lancaster, California
93534-7059 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices, including
zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>661-723-7723 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Registrant&rsquo;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Former name or former address, if changed since
last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: left">&#9744;</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: left">&#9744;</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: left">&#9744;</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: left">&#9744;</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14.25pt; text-indent: -14.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: right; margin-bottom: 0">Emerging Growth Company &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14.25pt; text-indent: -14.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 2.01 Completion of Acquisition or Disposition
of Assets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As previously reported on that certain Current
Report on Form 8-K filed by Simulations Plus, Inc., a California corporation (the &ldquo;Company&rdquo;), with the Securities and
Exchange Commission (the &ldquo;SEC&rdquo;) on May 1, 2017 (the &ldquo;May Form 8-K&rdquo;), on May 1, 2017, Simulations Plus,
Inc., a California corporation (the &ldquo;Company&rdquo;), entered into a Stock Purchase Agreement (the &ldquo;Agreement&rdquo;)
with DILIsym Services, Inc., a North Carolina corporation (&ldquo;DILIsym&rdquo;), the shareholders of DILIsym (the &ldquo;DILIsym
Shareholders&rdquo;) and Brett A. Howell, the representative of the DILIsym Shareholders (the &ldquo;DILIsym Shareholders Representative&rdquo;),
each, a &ldquo;Party,&rdquo; and collectively, the &ldquo;Parties.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 1, 2017, the Company consummated the
acquisition of all outstanding capital stock of DILIsym pursuant to the terms of the Agreement and DILIsym became a wholly owned
subsidiary of the Company (the &ldquo;Acquisition&rdquo;). Under the terms of the Agreement, the Company: (1) paid to the DILIsym
Shareholders Five Million Dollars ($5,000,000) payable at the closing of the Acquisition (the &ldquo;Closing&rdquo;) subject to
certain adjustments and holdbacks as provided in the Agreement and as more fully described below; and (2) will pay to the DILIsym
Shareholders certain earn-out payments, to be measured by the earnings of DILIsym before income taxes, payable following the Closing,
as more particularly described in the Agreement and as more fully described below (the &ldquo;Earn-out Payments&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">On June 1, 2017, the Company paid
the DILIsym Shareholders total cash consideration of $4,515,982; which such amount included $515,982 in working capital left in
DILIsym&rsquo;s accounts in excess of the amount required under the Agreement,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">At the holdback release date, eighteen
months from the Closing and subject to any offsets, the Company will pay $1,000,000 of holdback consideration; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">In addition, the Company may pay
up to an additional $5,000,000 in Earn-out Payments over the 3 years following the Closing if and when such Earn-out Payments become
due and payable, and subject to certain offsets as provided in the Agreement, according to the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As previously reported on the May Form 8-K,
on May 1, 2017, Dr. Daniel Weiner was appointed as a member of the Board of Directors of the Company and Dr. Weiner also serves
on the Board of Directors of DILIsym. Immediately prior to the Closing, Dr. Weiner owned 5,000 shares of DILIsym&rsquo;s common
stock (less than one percent of DILIsym&rsquo;s outstanding shares). At the closing of the Acquisition, Dr. Weiner received approximately
$29,000 in cash consideration of the sale of his shares of DILIsym to the Company and may receive up to an additional $35,000 upon
any payment of the holdback consideration and/or Earn-out Payments. The consideration for the purchase of the capital stock of
DILIsym was determined by arms&rsquo;-length negotiations between the Company and DILIsym prior to Dr. Weiner&rsquo;s appointment
to the Board of Directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 7.01 Regulation FD Disclosure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 1, 2017, the Company issued a press
release announcing that it has consummated the transaction contemplated by the Agreement. A copy of the press release is attached
hereto as Exhibit 99.1 and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial
Statements of Business Acquired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As permitted by Item 9.01(a)(4) of Form 8-K,
the financial statements required by Item 9.01(a) of Form 8-K will be filed by the Company by an amendment to this Current Report
on Form 8-K not later than 71 days after the date upon which this Current Report on Form 8-K must be filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pro
Forma Financial Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As permitted by Item 9.01(b)(2) of Form 8-K,
the pro forma financial information required by Item 9.01(b) of Form 8-K will be filed by the Company by an amendment to this Current
Report on Form 8-K not later than 71 days after the date upon which this Current Report on Form 8-K must be filed</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 2; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">99.2</TD><TD STYLE="text-align: justify">Press release Dated June 1, 2017</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37.1pt">The information in this
Current Report on Form 8-K furnished pursuant to Item 7.01, including the exhibit thereto (the &ldquo;Item 7.01 Information&rdquo;)
is not deemed to be &ldquo;filed&rdquo; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (&ldquo;Exchange
Act&rdquo;), or otherwise subject to the liabilities of that section, and such information is not incorporated by reference into
any registration statements or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, whether
made before or after the date hereof, regardless of the general incorporation language contained in such filing, except as shall
be expressly set forth by specific reference to this filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37.1pt">By providing the Item
7.01 Information, the Company makes no admission as to the materiality of the Item 7.01 Information. The Item 7.01 Information
is intended to be considered in the context of the Company&rsquo;s filings with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;)
and other public announcements that the Company makes, by press release or otherwise, from time to time. The Company undertakes
no duty or obligation to publicly update or revise the Item 7.01 Information, although it may do so from time to time as its management
believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press
releases or through other public disclosure</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37.1pt">This Current Report on
Form 8-K may contain forward-looking statements that are made pursuant to the safe harbor provisions of Section 21E of the Exchange
Act. The forward-looking statements in this Current Report on Form 8-K are not historical facts, do not constitute guarantees of
future performance and are based on numerous assumptions which, while believed to be reasonable, may not prove to be accurate.
Any forward-looking statements in this Current Report on Form 8-K do not constitute guarantees of future performance and involve
a number of factors that could cause actual results to differ materially, including risks more fully described in the Company&rsquo;s
most recently filed Quarterly Report on Form 10-Q and Annual Report on Form 10-K. The Company assumes no obligation to update any
forward-looking information contained in this Current Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37.1pt">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">SIMULATIONS PLUS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: right"><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;/s/ John R. Kneisel</FONT></TD>
    <TD STYLE="width: 17%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>John R. Kneisel</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Chief Financial Officer</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: <B>June 21, 2017</B></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>simulations_8k-ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="logo.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">For Further Information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Simulations Plus, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">42505 10<SUP>th</SUP> Street West</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Lancaster, CA 93534-7059</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt"><B>CONTACT</B>:</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><U>Simulations Plus Investor Relations</U></TD>
    <TD><U>Hayden IR</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Ms. Renee Bouche</TD>
    <TD>Mr. Cameron Donahue</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>661-723-7723</TD>
    <TD>651-653-1854</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>renee@simulations-plus.com</TD>
    <TD>cameron@haydenir.com</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">For Immediate Release:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">June 1, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Simulations Plus Closes Acquisition of DILIsym
Services, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>LANCASTER, CA, June 1, 2017 &ndash; </B>Simulations
Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development,
today announced that the Stock Purchase Agreement (the &ldquo;Agreement&rdquo;) with DILIsym Services, Inc. (&ldquo;DILIsym&rdquo;)
of Research Triangle Park, North Carolina, announced on May 1, 2017, has been closed as of today, and DILIsym is now a division
of Simulations Plus. DILIsym is the global leader in the simulation of drug-induced liver injury (&ldquo;DILI&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the Agreement, upon closing, DILIsym
has become a wholly owned subsidiary of Simulations Plus and will continue to operate under the DILIsym name. As a result of this
accretive acquisition, the total number of Simulations Plus employees is increasing from 70 to 81. DILIsym realized revenues of
just over $3 million in 2016 with $720,000 in net earnings. Management expects to grow the business going forward.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Walt Woltosz, chairman and chief executive
officer of Simulations Plus, Inc., said, &ldquo;This is an exciting step forward for both Simulations Plus and DILIsym Services,
Inc. Drug-induced liver injury can result in failed clinical trials and in drugs being withdrawn from the market, both of which
are a financial disaster to a pharmaceutical company. Thus, it is important to identify new drug compounds that may produce DILI
as early as possible in the development cycle in order to eliminate them and to focus resources on compounds more likely to be
successful. Dr. Brett Howell has been appointed president of the division. Dr. Scott Siler has been appointed chief scientific
officer. Dr. Bud Nelson will serve as director of operations. We look forward to collaborating with the management team of DILIsym
to advance further the study and simulation of drug-induced liver injury.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dr. Howell added, &ldquo;I look forward to
working with Walt, the scientists at Simulations Plus and Cognigen, and the board of directors to ensure the continued success
of our company. I am excited about the opportunities this combination of technologies affords for the future of clinical pharmacology.
The strong interest in pharmaceutical companies and regulatory agencies in avoiding DILI for new drugs fuels our DILI-sim Initiative.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The DILI-sim Initiative, under the direction
of Dr. Paul Watkins, professor at the University of North Carolina and world-renown expert on DILI, is a consortium of 12 pharmaceutical
companies that fund, guide, and support through their technical expertise the further development of the DILIsym software. Dr.
Watkins is also chair of the Company&rsquo;s prestigious scientific advisory board, made up of global leaders in the study of drug-induced
liver injury.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>The Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Agreement called for the acquisition of
DILIsym Services, Inc. to become a wholly owned subsidiary of Simulations Plus with the subsidiary continuing to operate under
the name DILIsym.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the terms of the Agreement, Simulations
Plus will pay the shareholders of DILIsym Services, Inc. a potential total all-cash consideration of $10 million for all of the
shares of DILIsym. The initial payment of $5 million was adjusted to approximately $4.5 million to reflect a $1 million, 18-month
holdback to satisfy any indemnifiable claims that may arise pursuant to the terms of the Agreement, and an addition of just over
$500,000 for excess cash and working capital left in the business by the shareholders. A three-year earn-out period will exist
following the closing during which up to an additional $5 million, based on the adjusted pretax income of the DILIsym division,
can be earned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Excel Partners, an investment bank with offices
in New York and Los Angeles, acted as exclusive financial advisor to Simulations Plus in connection with this transaction. Procopio,
Cory, Hargreaves &amp; Savitch LLP served as legal counsel to Simulations Plus in connection with this transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About Simulations Plus, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Simulations Plus, Inc., is a premier developer
of groundbreaking drug discovery and development simulation and modeling software that is licensed to and used in the conduct of
drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. The company&rsquo;s
Cognigen subsidiary in Buffalo, New York, provides clinical trial data analysis and consulting expertise to pharmaceutical companies
across the globe. Simulations Plus is headquartered in Southern California and trades on the NASDAQ Capital Market under the symbol
&ldquo;SLP.&rdquo; For more information, visit our Web site at www.simulations-plus.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About DILIsym Services, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">DILIsym Services, Inc., was spun out of the
now-defunct Hamner Institute in Research Triangle Park, North Carolina in 2014. The company is the leading provider of drug-induced
liver injury simulation and consulting services. More information is available on the company&rsquo;s Web site at <U>www.DILIsymServices.com.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Safe Harbor Statement Under the Private
Securities Litigation Reform Act of 1995</B> &ndash; With the exception of historical information, the matters discussed in this
press release are forward-looking statements that involve a number of risks and uncertainties. Words like &ldquo;believe,&rdquo;
&ldquo;expect&rdquo; and &ldquo;anticipate&rdquo; mean that these are our best estimates as of this writing, but that there can
be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ
significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to:
our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by
our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to
attract and retain highly qualified technical staff, our ability to properly manage the new combined company, and a sustainable
market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities
and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Follow us on Twitter <FONT STYLE="color: blue"><U>| </U></FONT>LinkedIn</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  R 0@# 2(  A$! Q$!_\0
M'    @,! 0$!              <$!08#" (!_\0 .A   0,# P(#!0<"!04
M     0(#!  %$082(0<3,4%1%")A<8$(%2,R4I&A,[$6%R0T0F)C@L'A_\0
M&0$!  ,! 0                $"! ,%_\0 *1$  @(! P,#! ,!
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,HH HHHH HHHH#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
